
## Ge Wang

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7454461/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 559-568.	8.1	121
2	Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer. Scientific Reports, 2020, 10, 20924.	3.3	6
3	Identification of low-density lipoprotein receptor class A domain containing 4 (LDLRAD4) as a prognostic indicator in primary gastrointestinal stromal tumors. Current Problems in Cancer, 2020, 44, 100593.	2.0	4
4	Clinical significance of interleukin‑10 concentration in the cerebrospinal fluid of patients with primary central nervous system lymphoma. Oncology Letters, 2020, 21, 1-1.	1.8	10
5	High expression of c‑Met and EGFR is associated with poor survival of patients with glottic laryngeal squamous cell carcinoma. Oncology Letters, 2018, 15, 931-939.	1.8	11
6	Genistein promotes ionizing radiation-induced cell death by reducing cytoplasmic Bcl-xL levels in non-small cell lung cancer. Scientific Reports, 2018, 8, 328.	3.3	28
7	The diagnostic role and dynamic changes in cerebrospinal fluid neopterin during treatment of patients with primary central nervous system lymphoma. Cancer Medicine, 2018, 7, 3889-3898.	2.8	8
8	Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study. BMC Cancer, 2017, 17, 245.	2.6	25
9	EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment. Cancer Biology and Therapy, 2016, 17, 320-327.	3.4	30
10	MicroRNA-21 regulates the expression of BTG2 in HepG2 liver cancer cells. Molecular Medicine Reports, 2015, 12, 4917-4924.	2.4	35
11	Clinical efficacy of percutaneous vertebroplasty combined with intensity-modulated radiotherapy for spinal metastases in patients with NSCLC. OncoTargets and Therapy, 2015, 8, 2139.	2.0	3
12	One-Carbon Metabolic Factors and Risk of Renal Cell Cancer: A Meta-Analysis. PLoS ONE, 2015, 10, e0141762.	2.5	10
13	Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. World Journal of Hepatology, 2015, 7, 1964.	2.0	107
14	MicroRNAs involved with hepatocellular carcinoma (Review). Oncology Reports, 2015, 34, 2811-2820.	2.6	65
15	BTG2: A rising star of tumor suppressors (Review). International Journal of Oncology, 2015, 46, 459-464.	3.3	105
16	APE1 promotes antioxidant capacity by regulating Nrf-2 function through a redox-dependent mechanism. Free Radical Biology and Medicine, 2015, 78, 11-22.	2.9	15
17	High-incidence of PTEN mutations in Chinese patients with primary small cell carcinoma of the esophagus. BMC Cancer, 2014, 14, 19.	2.6	12
18	A method for generating large datasets of organ geometries for radiotherapy treatment planning studies. Radiology and Oncology, 2014, 48, 408-415.	1.7	3

#	Article	IF	CITATIONS
19	Identification and Characterization of Mitochondrial Targeting Sequence of Human Apurinic/Apyrimidinic Endonuclease 1. Journal of Biological Chemistry, 2010, 285, 14871-14881.	3.4	77
20	Rapid induction of mRNA forTecgenes by hepatopoietin and partial hepatectomy. Chinese Journal of Digestive Diseases, 2002, 3, 154-158.	1.0	0